PMID- 33517299
OWN - NLM
STAT- MEDLINE
DCOM- 20210205
LR  - 20210205
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 41
IP  - 2
DP  - 2021 Feb
TI  - Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment 
      for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
PG  - 927-936
LID - 10.21873/anticanres.14846 [doi]
AB  - BACKGROUND/AIM: Limited published real-world data describe adverse events (AEs) 
      among patients treated for mantle-cell lymphoma (MCL). The aim of this 
      retrospective study was to describe treatment patterns, AEs, and associated 
      healthcare costs. PATIENTS AND METHODS: Patients had two or more claims coded for 
      MCL diagnosis, the first claim date (07/01/2012-05/31/2017) was the index date. 
      Patients with pre-index MCL diagnosis or systemic treatment, or hematopoietic 
      stem cell transplantation were excluded. Cohorts by regimen were followed for up 
      to three lines of therapy. RESULTS: Patients (n=395; median age 72 years; 31% 
      female) were observed over a total of 576 lines of therapy, the most common being 
      bendamustine plus rituximab; rituximab monotherapy; R-CHOP; and ibrutinib. The 
      most frequent AEs were hypertension (40.5%), anemia (37.7%), and infection 
      (36.1%). However, hepatotoxicity ($19,645), stroke ($18,893), and renal failure 
      ($9,037) were associated with the highest medical costs per patient per month. 
      CONCLUSION: Among patients receiving common systemic treatments for MCL, AEs 
      occurred frequently; some imposed substantial inpatient care costs.
CI  - Copyright (c) 2021 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kabadi, Shaum M
AU  - Kabadi SM
AD  - Epidemiology and Real-World Evidence, AstraZeneca, Oncology, Gaithersburg, MD, 
      U.S.A.
FAU - Byfield, Stacey Dacosta
AU  - Byfield SD
AD  - Health Economics and Outcomes Research, Optum, Eden Prairie, MN, U.S.A.; 
      staceydacostabyfield@uhg.com.
FAU - LE, Lisa
AU  - LE L
AD  - Health Economics and Outcomes Research, Optum, Eden Prairie, MN, U.S.A.
FAU - Olufade, Temitope
AU  - Olufade T
AD  - Health Economics and Outcomes Research, AstraZeneca, Gaithersburg, MD, U.S.A.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Piperidines)
RN  - 0 (R-CHOP protocol)
RN  - 1X70OSD4VX (ibrutinib)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 981Y8SX18M (Bendamustine Hydrochloride)
RN  - JAC85A2161 (Adenine)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adenine/adverse effects/analogs & derivatives/economics/therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse 
      effects/economics/therapeutic use
MH  - Bendamustine Hydrochloride/adverse effects/economics/therapeutic use
MH  - Chemical and Drug Induced Liver Injury/*economics
MH  - Cyclophosphamide/adverse effects/economics/therapeutic use
MH  - Doxorubicin/adverse effects/economics/therapeutic use
MH  - Female
MH  - Health Care Costs
MH  - Humans
MH  - Lymphoma, Mantle-Cell/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Piperidines/adverse effects/economics/therapeutic use
MH  - Prednisone/adverse effects/economics/therapeutic use
MH  - Renal Insufficiency/chemically induced/*economics
MH  - Retrospective Studies
MH  - Rituximab/adverse effects/economics/therapeutic use
MH  - Stroke/chemically induced/*economics
MH  - Vincristine/adverse effects/economics/therapeutic use
OTO - NOTNLM
OT  - Mantle-cell lymphoma
OT  - adverse events
OT  - healthcare costs
OT  - retrospective cohort study
EDAT- 2021/02/01 06:00
MHDA- 2021/02/07 06:00
CRDT- 2021/01/31 20:36
PHST- 2020/12/09 00:00 [received]
PHST- 2020/12/23 00:00 [revised]
PHST- 2021/01/07 00:00 [accepted]
PHST- 2021/01/31 20:36 [entrez]
PHST- 2021/02/01 06:00 [pubmed]
PHST- 2021/02/07 06:00 [medline]
AID - 41/2/927 [pii]
AID - 10.21873/anticanres.14846 [doi]
PST - ppublish
SO  - Anticancer Res. 2021 Feb;41(2):927-936. doi: 10.21873/anticanres.14846.